A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Genentech, Inc.
Hoffmann-La Roche
Hoffmann-La Roche
Dana-Farber Cancer Institute
Hoffmann-La Roche
Jonsson Comprehensive Cancer Center
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Hoffmann-La Roche
Gilead Sciences
Hoffmann-La Roche
Hoffmann-La Roche
Australasian Leukaemia and Lymphoma Group
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Medical College of Wisconsin
University of Pennsylvania
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)